What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to announce Abbott Laboratories' financial results for the fourth quarter and full year 2018, as detailed in an accompanying press release furnished as an exhibit.

What are non-GAAP financial measures and why does Abbott use them?

Non-GAAP financial measures are financial metrics that exclude certain items from GAAP (Generally Accepted Accounting Principles) results. Abbott uses them to provide investors with a clearer view of its ongoing business performance by adjusting for unusual or unpredictable factors such as acquisition costs, restructuring charges, and gains/losses from asset sales.

Are there any significant one-time events mentioned that impact the results?

Yes, the filing mentions a gain associated with the sale of the Medical Optics business, as well as expenses related to acquisitions, restructuring, cost reduction initiatives, and early extinguishment of debt, which are adjusted for in the non-GAAP measures.

What is the key takeaway for investors regarding the financial measures presented?

Investors should understand that while Abbott's non-GAAP measures aim to provide better insights into operational performance, they should always be considered in conjunction with, and not as a substitute for, the company's GAAP-based financial statements.

ABT 8-K: Earnings & Results

Summary

Abbott Laboratories (ABT) filed an 8-K on January 23, 2019, to announce its fourth quarter and full year 2018 financial results. The report primarily furnishes a press release detailing these results, which includes the use of non-GAAP financial measures. Investors should note that Abbott's management utilizes these non-GAAP figures to offer a clearer view of ongoing business performance, adjusting for items such as acquisition and restructuring expenses, gains from asset sales (specifically the Medical Optics business), tax reform impacts, debt extinguishment costs, and impairment charges. While these non-GAAP measures, which exclude intangible amortization, are presented to provide enhanced visibility into operational results and are used internally by management, investors are advised to consider them alongside GAAP-based financial measures. The filing also confirms the Chief Financial Officer, Brian B. Yoor, signed the report, indicating the official release of this financial information.

Key Highlights

1Abbott Laboratories announced its Q4 and full-year 2018 financial results on January 23, 2019.
2The 8-K filing includes a press release (Exhibit 99.1) containing the detailed financial results.
3Abbott utilizes non-GAAP financial measures to present its results, excluding certain specified items.
4Adjustments in non-GAAP measures include expenses from acquisitions, restructuring, cost reduction initiatives, and debt extinguishment.
5A gain from the sale of the Medical Optics business is also a factor in the non-GAAP adjustments.
6The company provides these non-GAAP measures to offer investors better insight into ongoing business performance, alongside GAAP measures.

ABBOTT LABORATORIES 8-K Report, Financial Results (Jan 23, 2019)

Summary

Key Highlights

Frequently Asked Questions